Abbvie INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE

14 Feb 2025

ABBV

10-K: AbbVie's 2024 10-K Filing: Diversified Portfolio Drives Revenue Growth Amid Humira Biosimilar Competition

AbbVie's 2024 Form 10-K reveals a 4% revenue increase driven by Skyrizi and Rinvoq, offsetting Humira's biosimilar impact, alongside strategic acquisitions and pipeline advancements.

NYSE

20 Feb 2024

ABBV

Abbvie INC

10-K: AbbVie Details Securities and Corporate Governance in 10-K Filing

AbbVie's 10-K filing outlines the company's registered securities, capital stock structure, and various corporate governance provisions.